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INTRODUCTION
Elucidation of etiological factors of schizophrenia remains 
a major challenge for researchers. In the last two decades sev-
eral Genome Wide Association Studies (GWAS) have been 
performed to unravel genetic causes of the disease.1-3 Simul-
taneously, hundreds or even thousands of single nucleotide 
polymorphisms (SNPs) were reported, which individually 
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could explain only a small fraction of the genetic contribution 
to the disease; however, cumulative effect of these risk variants 
may offer a larger share in genetic architecture of disease.4
The Schizophrenia Psychiatric GWAS Consortium (PGC) 
has recently reported the largest schizophrenia genome-wide 
association study comprising 36,989 cases and 113,075 con-
trols. This study revealed 108 loci with genome-wide signifi-
cance, including 83 previously reported loci.3 In the present 
study we selected a set of statistically top schizophrenia genes, 
MIR137 and two of its putative targets (CACNA1C and CSMD1) 
along with potential therapeutic targets of schizophrenia DRD2 
and GRM3 from the above report.
MIR137 encodes microRNA (miR-137), a well-known reg-
ulator of adult neurogenesis,5 which is one of the risk genes in-
volved in the etiology of range of neuropsychiatric disorders.2,3 
A number of GWAS revealed rs1625579 (located within intron 
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of MIR137) indicating robust association with schizophre-
nia.2,6,7 CACNA1C encodes the alpha 1C subunit of the L-type 
voltage-gated calcium channel and variations in it have con-
sistently been reported as a potential risk factor for schizo-
phrenia, bipolar and major depressive disorders.8-10 Several 
genetic association studies have identified CACNA1C intron-
ic SNPs rs1006737 (A-allele) and rs4765905 (C allele) as risk 
factors for schizophrenia.2,11,12 CSMD1, the CUB and Sushi 
multiple domains-1 is a susceptibility gene for schizophrenia 
and multiple neurodevelopmental disorders.13,14 The SNP 
rs10503253 (A allele), located within CSMD1 gene has been 
reported to be a risk factor for schizophrenia.15,16
Glutamate is most abundant excitatory neurotransmitter in 
the central nervous system (CNS). Glutamate neurotransmis-
sion is essential for several brain functions such as learning, 
memory, cognition, neural development and motor control. 
Furthermore, glutamate neurotransmitter hypofunction might 
be involved in pathophysiology of schizophrenia. GRM3 (type-
3 metabotropic glutamate receptor) encodes the mGluR3 which 
regulates glutamate neurotransmission and synaptic plastici-
ty. The functional polymorphism rs6465084 (GRM3) has 
been found to be associated with poor performance of cog-
nitive function in schizophrenia.17,18 Recently, rs12704290 and 
rs148754219 in GRM3 have gained much attention as schizo-
phrenia risk variants.3,19
The Dopamine hypothesis is the oldest theory proposing that 
impairments in dopamine neurotransmission systems are 
involved in pathophysiology of schizophrenia. The dopamine 
receptor type 2 (DRD2) is associated with schizophrenia as 
well as highlighted as a potential drug target of schizophrenia. 
Moreover, genetic variation within DRD2 is associated with 
schizophrenia at genome-wide significance level.3,20 The func-
tional SNP rs1076560 in DRD2 gene is one of the known risk 
variants for schizophrenia.21
There is no data available on the prevalence of schizophre-
nia in the Pakistani population mainly due to low literacy, lack 
of disease awareness and various social taboos related to psy-
chiatry disorders. No study has so far been conducted to see 
whether MIR137, CACNA1C, CSMD1, DRD2 and GRM3 con-
fer a risk for schizophrenia in Pakistani population. Based on 
the reported evidence from several GWAS, we selected the top 
eight SNPs from the above reported genes to study their asso-
ciation with schizophrenia in Pakistani population. 
METHODS
Subjects
This study was approved by the local research ethics com-
mittee of the National Institute for Biotechnology and Genetic 
Engineering (NIBGE), Faisalabad, Pakistan. All the subjects, 
both control and patients enrolled for this study were of Pak-
istani descend. This study included 508 unrelated patients with 
schizophrenia comprising of 382 men and 126 women with 
a mean age of 46 years and 300 unrelated healthy controls 
comprising of 175 men and 125 women, with a mean age of 
44 years. Informed written consent was obtained from all the 
subjects or their legal guardians after explaining this study in 
their native language. Schizophrenia was diagnosed on the ba-
sis of clinical history and symptoms based on the Diagnostic 
and Statistical Manual of Mental Disorders 4th ed (DSM-IV). 
All the patients were examined and diagnosed independently 
by at least two psychiatrists from local hospitals
SNP selection
The largest schizophrenia genome-wide association study 
of 36,989 cases and 113,075 controls has revealed 108 loci with 
genome-wide significance.3 We selected a set of statistically 
top hits; MIR137 and two of its putative targets (CACNA1C and 
CSMD1) and potential drugs’ targets of schizophrenia DRD2 
and GRM3 from this study. After a thorough literature review 
of research published prior to January 2015, a total of eight risk 
SNPs (rs1625579, rs1006737, rs4765905, rs10503253, rs1076560, 
rs12704290, rs6465084, and rs148754219) were chosen for anal-
ysis. Selected SNPs have shown significant positive association 
(MAF >0.05) with schizophrenia in multiple populations. 
Genotyping
In this study, we adopted a case-control approach to test the 
hypothesis that these risk alleles are associated with schizo-
phrenia in Pakistani population. Genomic DNA was extracted 
from peripheral blood according to standard organic proto-
cols. Mismatch primers were designed for Restriction Frag-
ment Length Polymorphism (RFLP) (Table 1). For genotyp-
ing polymerase chain reaction (PCR) was performed in a total 
volume of 10 µL containing 50 ng of genomic DNA, 10X key 
buffer (VWR) 1 µL, 2.5 mM of dNTP-Mix, 10 pmol of each 
primer, 0.15 µL of ampli-Taq DNA polymerase (VWR) and 
nuclease-free water. The reaction was performed under fol-
lowing cycling condition: initial denaturation at 95°C for 5 
min, 40 cycles of 95°C for 15 sec, 58°C and 72°C for 30 and 
45 sec respectively and final extension for 5 min at 72°C. Am-
plification was visualized using 1% agarose gel and amplicons 
were digested overnight at 37°C with appropriate enzymes. Fi-
nally digested product was resolved on 2% agarose gel for ge-
notyping. Randomly selected PCR products were sequenced 
on an ABI 3130XL genetic analyzer (Applied Biosystems) using 
BigDye Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosys-
tems) to verify the RFLP results.
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Statistical analysis
The allele and genotype frequency analysis were conducted 
using SPSS version 20 (IBM Corp., Armonk, NY, USA). To check 
the significance of genotype and allele frequencies in cases 
and control group; chi-square analysis was used. The odds 
ratios were also calculated to see the effect of different groups 
on alleles in SNPs.
RESULTS 
A total of eight SNPs were genotyped in 808 samples includ-
ing 508 patients and 300 controls. Allelic and genotyping fre-
quencies including odds ratios for these eight SNPs in patients 
and controls are described in Table 2.
In the genotype and allele frequencies of rs4765905, rs1076560 
and rs6465084a significant difference was found between pa-
tients and control group (p=0.000) (Table 2). The remaining 
SNPs did not show any significant difference between schizo-
phrenia patients and control group (Table 2). To examine wheth-
er the patients’ age of onset in schizophrenia has any associa-
tion with these variants, we split the patients’ data set into two 
groups, one with the onset of disease before 25 years and sec-
ond after 25 years of age. The data was analysed as described 
above, only rs6465084 was found associated with age of onset 
before 25 years (Table 3). 
DISCUSSION
In this study, we conducted the first Pakistani population 
based genetic association of top schizophrenia candidates 
MIR137, CACNA1C, CSMD, DRD3, and GRM3. CACNA1C 
(12p13.3) encodes α-1C subunit of the L-type voltage-gated 
calcium channel, which has been reported to be strongly asso-
ciated with schizophrenia in several association studies.2,8,10,22 
CACNA1C play an important role in development of central 
nervous system, associated with poor executive function and 
especially exhibit a profound reduction of bilateral hippocam-
pal activation that leads to impaired memory function.23,24 In 
a recent GWAS of schizophrenia, one of the top statistical hit 
was rs4765905 located within CACNA1C.2 In the present 
study, the SNP rs4765905 showed significant allelic and geno-
typic association of risk allele C with schizophrenia (Table 2). 
Hamshere and colleagues8 combined additional samples to 
the analysis performed by Ripke et al.2 and replicated genome 
wide significant association of rs4765905 with schizophrenia. 
A recent cross population study revealed significant associa-
tion of rs4765905 with schizophrenia (p=0.013999) in Han 
Chinese samples providing more support to the earlier find-
ings.12 This positive association of rs4765905 with schizo-
phrenia in Pakistani subjects depicted in the present study pro-Ta
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vides additional evidence to support the role of CACNA1C in 
schizophrenia susceptibility. Several GWAS reported another 
variant rs1006737 in CACNA1C gene associated with schizo-
phrenia. Allele A of rs1006737 has been reported to be more 
consistently associated with schizophrenia as a risk allele in 
several GWAS followed by functional studies.2,8,23,25,26 We did 
not find genetic association of risk allele A among the patients 
recruited in this study. Negative association of rs1006737 
with schizophrenia has also been reported in studies conduct-
ed on Chinese and Japanese patients.27,28 The negative associ-
ation in the current study might be due to relatively small sam-
ple size or the frequency of the risk A-allele considerably lower 
in samples of Asian origin than in Caucasian as discussed by 
Hori and colleagues.28
The functional variant rs1076560 in DRD2 gene affects the 
balance of expression from D2S (D2 short isoform) to D2L 
(D2 long isoform), which in turn influences the dopaminergic 
signalling. The risk allele (T) of rs1076560 decreases expres-
sion of the DRD2 short D2 isoform, affects the brain activity 
and connectivity during emotion processing.29 This allele was 
associated with impairments in decision-making and behav-
ioural effects of schizophrenia patients.30 There is a strong evi-
dence that this variant increases the risk of psychosis-related 
phenotypes, including schizophrenia.27,31 The positive associ-
ation of rs1076560 in Pakistani samples (p=0.000) contrib-
utes further in support of existing evidence on the role of this 
SNP in predisposition to schizophrenia.
The type-3 metabotropic glutamate receptor gene (GRM3) 
is a candidate gene as well as one of the potential therapeutic 
targets for schizophrenia.3 In this study we found a significant 
association of allele A and genotype AA of rs6465084 with 
schizophrenia patients. These results are in line with previous 
studies, which reported that functional polymorphism rs6465084 
(GRM3) has been found associated with poor performance 
cognitive function of schizophrenia.3,17 In the present study, we 
could not find any significant differences in genotype and allele 
frequencies of rs1625579, rs1006737, rs10503253, rs12704290 
and rs148754219 between patients and controls. Our results 
are in agreement with some other studies that reported nega-
tive association of these SNPs with schizophrenia.32-34
Our second hypothesis was that these risk alleles are asso-
ciated with age of disease onset; to test this we divided our pa-
tients into two cohorts; the group with disease onset before 
25 years and that with after 25 years. In this analysis we found 
a significant association of rs6465084 with age of onset be-
fore 25 years (Table 3). These results provide additional indi-
Table 2. Allele and genotype frequency of SNPs association analysis in patients vs. controls
Gene SNP/position Allele frequency (%) p value Genotype frequency (%) p value OR/95% CI
MIR137 rs1625579
SCZ
CTR
T
774 (79.79)
452 (76.61)
G
196 (20.21)
138 (23.39)
0.137 TT
378 (77.9)
223 (75.6)
TG
018 (3.7%)
006 (2.0)
GG
89 (18.4)
66 (22.4)
0.192 1.21 (0.94–1.54)
CACNA1C rs1006737
SCZ
CTR
G
870 (88.06)
524 (87.92)
A
118 (11.94)
072 (12.08)
0.935 GG
393 (79.6)
235 (78.9)
GA
084 (17.0)
054 (18.1)
AA
17 (3.4)
09 (3.0)
0.885 0.99 (0.72–1.35)
CACNA1C rs4765905
SCZ
CTR
G
769 (79.61)
544 (90.97)
C
197 (20.39)
054 (9.03)
0.000 GG
310 (64.2)
254 (84.9)
GC
149 (30.8)
036 (12.0)
CC
24 (5.0)
09 (3.0)
0.000 2.58 (1.87–3.56)
CSMD1 rs10503253
SCZ
CTR
C
745 (73.62)
423 (72.43)
A
267 (26.38)
161 (27.57)
0.607 CC
284 (56.1)
152 (52.1)
CA
177 (35.0)
119 (40.8)
AA
45 (8.9)
21 (7.2)
0.238 0.94 (0.75–1.18)
DRD2 rs1076560
SCZ
CTR
C
467 (77.83)
673 (66.90)
A
133 (22.17)
333 (33.1)
0.000 CC
189 (37.6)
174 (58.0)
CA
295 (58.6)
119 (39.7)
AA
19 (3.8)
07 (2.3)
0.00 1.77 (1.40–2.24)
GRM3 rs12704290
SCZ
CTR
G
979 (96.93)
590 (98.33)
A
031 (3.07)
010 (1.67)
0.084 GG
478 (94.7)
290 (96.7)
GA
023 (4.6)
010 (3.3)
AA
04 (0.8)
00 (0.0)
0.21 0.56 (0.26–1.10)
GRM3 Rs6465084
SCZ
CTR
G
473 (50.97)
246 (41)
A
455 (49.03)
354 (59)
0.000 GG
064 (13.8)
012 (4.0)
GA
345 (74.4)
222 (74.0)
AA
55 (11.9)
66 (22.0)
0.00 0.69 (0.54–0.82)
GRM3 rs114875219
SCZ
CTR
G
986 (97.62)
593 (98.83)
A
024 (2.38)
007 (1.17)
0.000 GG
482 (95.4)
293 (97.7)
GA
022 (4.4)
007 (2.3)
AA
01 (0.2)
00 (0.0)
0.24 0.49 (0.21–1.13)
SNP: Single Nucleotide Polymorphism
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cation that genetic variants significantly contribute to the age 
of onset in individuals with schizophrenia. There was no sig-
nificant association between remaining risk variants and age 
of onset, whereas only rs1625579 and rs12704290 showed 
significant allelic frequency (p=0.03) between AAO<25 and 
AAO>25 years (Table 3).
The negative association between schizophrenia and 
rs1006737, rs1625579, rs10503253, rs12704290, and rs148754219 
in our samples probably reflects disease heterogeneity influ-
enced by the ethnic difference. It is also possible that our rela-
tively small sample size for the genetic association study might 
be the reason for non-significant result.
The DRD2 and GRM3 are the most promising targets of ef-
fective antipsychotic drugs for treatment of psychiatric disor-
ders specially schizophrenia.3 Interestingly positive associa-
tion of rs1076560 (DRD2) and rs6465084 (GRM3) in Pakistani 
population provides additional line of evidence to the most pre-
dominant hypothesis for therapeutic targets for schizophrenia.
In the present study, we found three SNPs (rs4765905, 
rs1076560 and rs6465084) with significant difference between 
the patient and control groups (p=0.000). However, rs1625579, 
rs1006737, rs10503253, rs12704290, and rs148754219 did not 
show any significant difference between schizophrenia pa-
tients and healthy controls. These results provide important 
evidence for the establishment of rs4765905, rs1076560, and 
rs6465084as risk variants for schizophrenia in Pakistani pop-
ulation. However, we could not completely exclude the possi-
bility of other variants with schizophrenia susceptibility. Fur-
ther studies investigating the role of additional causative variants 
for schizophrenia in Pakistani population are required.
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